Latest Materials News

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Civmec Limited posted solid FY25 results with $810.6 million revenue and a strategic acquisition boosting its naval shipbuilding footprint. The company’s $1.25 billion order book and focus on low-carbon sectors set the stage for growth.

Civmec Limited reported a 21.6% drop in revenue and a 34% fall in net profit for FY2025, reflecting the impact of completed contracts. Despite this, the company maintained steady margins and increased its cash reserves, signaling resilience and ongoing growth potential.

BDO Audit has completed its review of HeraMED Limited’s half-year financial report for June 2025, confirming compliance with accounting standards but highlighting significant uncertainty over the company’s ability to continue as a going concern.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Alexium International Group Limited posted a 42.2% increase in net loss for FY2025, with revenues down 33.4% due to a soft US mattress market. Despite financial setbacks, the company advanced key technologies and announced leadership changes that could fuel future growth.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

The Federal Court of Australia has dismissed Harvey Norman’s appeal against prior legal declarations, setting the stage for an upcoming penalty hearing that could impact the retailer’s future.

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.